Brusatol dose-dependently suppresses proliferation and inflammatory mediator expression in TNF-α-induced HaCaT keratinocytes, ameliorates skin lesions and systemic dyslipidemia in mice, effectively normalizing serum TC and TG levels without inducing visceral organ toxicity. This evidence concerns the gene TNF and metabolic syndrome.